Recent Company News

• 02:06 AM ET Mar 19, 2026
  

  Molecular Partners to present new preclinical data on Radio-DARPins at the 3rd Global Radiopharmaceuticals Development Summit, taking place in Shanghai, China on 19-20 Mar (CHF 3.70, 0.00)

• 04:39 PM ET Mar 17, 2026
  

  Molecular Partners to present three posters at AACR 2026 Annual Meeting (CHF 3.15, 0.00)

• 04:22 PM ET Mar 12, 2026
  

  Molecular Partners reports financial results for FY25; provides pipeline update (CHF 3.77, 0.00)

• 03:19 PM ET Mar 02, 2026
  

  Transcript Intelligence: Molecular Partners at TD Cowen Health Care Conference

• 04:54 AM ET Feb 26, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:14 AM ET Feb 26, 2026
  

  Molecular Partners, Eckert & Ziegler enter agreement to enable development and manufacturing of Radio-DARPin therapeutics (CHF 3.74, 0.00)

• 10:03 AM ET Feb 25, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (270 total)

• 09:17 AM ET Feb 02, 2026
  

  Transcript Intelligence: Molecular Partners Business Update Call

• 01:06 AM ET Feb 02, 2026
  

  Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 (CHF 3.28, 0.00)

• 06:16 AM ET Jan 27, 2026
  

  Molecular Partners initiated buy at HC Wainwright ($4.00, 0.00)